ara 290 vs bpc-157 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 Diabetes | Molecular Medicine ReWire (ARA-290) Peptide Therapy Lincoln
Description
(2008) Biomaterials Study examining AOD 9604 effects on vascular endothelial growth factor production and neovascularization in engineered cartilage
doi: 10.1016/j.colsurfb.2018.11.025
Not a generic menu
Potential Research Applications: Neuroprotection and brain-gut axis studies Pulmonary function and airway inflammation models Immune system modulation and anti-inflammatory research Gastrointestinal motility and secretory regulation For laboratory research only
